Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety and Efficacy Evaluation of PD1-CD19-CART in Patients With Relapse/Refractory B-cell Lymphoma

Next Previous
Trial Profile

A Safety and Efficacy Evaluation of PD1-CD19-CART in Patients With Relapse/Refractory B-cell Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BRL 201 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors BRL Medicine

Most Recent Events

  • 04 Jun 2024 Long term follow-up results (n=25; From May 3, 2020, to August 10, 2021) assessing safety and efficacy of BRL-201 in patients treating relapsed or refractory non-Hodgkin's lymphoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 04 Jan 2024 Status changed from active, no longer recruiting to completed.
  • 13 Dec 2022 Results(As of July 19, 2022, n=21) assessing safety and efficacy of CAR-T cells (BRL-201) in treating adult patients with relapsed/refractory (r/r) B-NHL presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top